A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

About the study

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

* Have a body mass index (BMI) of:

≥30 kilogram per square meter (kg/m2) OR
≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
Have at least one unsuccessful attempt to lose weight by dieting

EXCLUSION CRITERIA

Exclusion Criteria:

Have a self-reported change in body weight >5 kg (11 pounds) within 90 days before screening
Have a prior or planned surgical treatment for obesity
Have type 1 diabetes or type 2 diabetes
Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Have had within the past 90 days before screening

acute myocardial infarction
cerebrovascular accident (stroke)
hospitalization for unstable angina, or
hospitalization due to congestive heart failure
Have New York Heart Association Functional Classification Class IV congestive heart failure
Have a history of chronic or acute pancreatitis
Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening